摘要
目的为黄芪与淫羊藿及相关复方制剂的临床应用提供参考。方法检索PubMed、中国知网、万方、维普数据库收载的黄芪与淫羊藿的药理活性及配伍应用相关文献,并进行归纳和总结。检索时限为2019年1月至2023年12月。结果与结论黄芪和淫羊藿均以多糖、黄酮及皂苷等为主要活性成分,有抗肿瘤、调节免疫、抗氧化、抗炎等多重药理作用。两者常作为补益中药配伍治疗以虚证为主的相关疾病,有协同增效作用。但目前两药配伍应用的相关研究较少,二者最佳配伍剂量、配伍前后药效机制均不明晰,后续需深入研究黄芪-淫羊藿配伍应用及相关作用机制,以期为两药及相关复方制剂的临床应用提供参考。
Objective To provide a reference for the clinical application of Astragali Radix,Epimedii Folium and related compound preparations.Method Relevant literatures on the pharmacological activities and compatibility applications of Astragali Radix and Epimedii Folium from PubMed,CNKI,WanFang,and VIP databases were searched,summarized and generalized from January 2019 to December 2023.Results and Conclusion Astragali Radix and Epimedii Folium are mainly composed of polysaccharides,flavonoids,and saponins as active components,which have multiple pharmacological effects such as anti-tumor,immune regulation,anti-oxidant,and anti-inflammatory.They are often used as tonic traditional Chinese medicine to compatibility therapy of related diseases mainly characterized by deficiency syndrome,and have a synergistic effect.However,there are currently limited research on the compatibility and application of the two Chinese herbs.The optimal dosage and pharmacological mechanisms of the two Chinese herbs before and after compatibility are unclear.Further research and explanation are needed on the compatibility and application of Astragali Radix-Epimedii Folium pair and its related mechanisms of action,in order to provide reference for the clinical application of the two Chinese herbs and related compound preparations.
作者
王嵩
施佐桥
李静
李国文
张彤
WANG Song;SHI Zuoqiao;LI Jing;LI Guowen;ZHANG Tong(Shanghai TCM-Integrated Hospital,Shanghai,China 200082;Shanghai University of TCM,Shanghai,China 201203)
出处
《中国药业》
2025年第16期128-128,I0001-I0008,共9页
China Pharmaceuticals
基金
全国中药特色技术传承人才培训项目[国中医药人教函〔2023〕96号]
上海市“医苑新星”青年医学人才培养资助计划项目[沪卫计人事〔2019〕72号]
上海中医药大学预算内科研项目[2021LK061]。
关键词
黄芪
淫羊藿
配伍
药理活性
临床应用
研究进展
Astragali Radix
Epimedii Folium
compatibility
pharmacological activites
clinical application
research progress
